Compare RKDA & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RKDA | BIAF |
|---|---|---|
| Founded | 2002 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8M | 6.6M |
| IPO Year | 2015 | 2022 |
| Metric | RKDA | BIAF |
|---|---|---|
| Price | $3.68 | $1.66 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 16.4K | ★ 108.8K |
| Earning Date | 11-07-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $5,173,000.00 | ★ $6,776,739.00 |
| Revenue This Year | $21.31 | N/A |
| Revenue Next Year | $28.33 | $20.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 12.31 | N/A |
| 52 Week Low | $2.53 | $1.25 |
| 52 Week High | $10.31 | $46.53 |
| Indicator | RKDA | BIAF |
|---|---|---|
| Relative Strength Index (RSI) | 47.28 | 46.56 |
| Support Level | $3.48 | $1.34 |
| Resistance Level | $3.76 | $1.54 |
| Average True Range (ATR) | 0.18 | 0.16 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 43.09 | 63.05 |
Arcadia Biosciences Inc is a producer and marketer of plant-based food and beverage products. It is engaged in science-based approaches to developing high-value crop improvements in wheat, soy, and hemp, designed to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health, and wellness products, and their viability for industrial applications. The company's consumer brands in the food, beverage, and body care categories include GoodWheat high-fiber pasta, Zola coconut water, and others.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.